# A Phase 2 Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome

> **NCT05740007** · PHASE2 · TERMINATED · sponsor: **Ironwood Pharmaceuticals, Inc.** · enrollment: 98 (actual)

## Conditions studied

- Interstitial Cystitis
- Bladder Pain Syndrome

## Interventions

- **DRUG:** IW-3300 rectal foam
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05740007
- **Lead sponsor:** Ironwood Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-03-28
- **Primary completion:** 2025-01-23
- **Final completion:** 2025-02-06
- **Target enrollment:** 98 (ACTUAL)
- **Why stopped:** Business decision
- **Last updated:** 2025-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05740007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05740007, "A Phase 2 Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05740007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*